Technical Data
P1000-49A
p21 (Activating Fragment 1, CAP20, CDK-interacting Protein 1, CIP1, Cyclin-dependent Kinase Inhibitor 1A, CDKN1A, CDKN1, DNA Synthesis Inhibitor, Melanoma Differentiation-associated Protein 6, MDA6, MDA6, p21CIP1, p21-CIP1, PIC1, SDI1, Wildtype p53 Activa
Description:
Protein p21, also known as wild-type p53-activated fragment 1 (WAF-1), inhibits cyclin dependent kinases and is regulated by p53; overexpression of this protein inhibits the proliferation of mammalian cells.

Applications:
Suitable for use in ELISA, Western Blot and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Immunohistochemistry: Paraffin
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG19L524Purified
SizeStorageShippingSourceHost
100ug-20CBlue IceHumanMouse
Concentration:
~1mg/ml
Immunogen:
Human p21 protein.
Purity:
Purified by ammonium sulfate precipitation.
Form
Supplied as a liquid in PBS, pH 7.4, 15mM sodium azide.
Specificity:
Recognizes human intracellular protein p21.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Kovaric, J., et al., (1996), Int. J. Oncol. suppl. 9, 835. 2. Horky, M., et al., (1997), "Induction of cell-cycle inhibitor p21 in rat ventricular myocytes during early postnatal transition from hyperplasia to hypertrophy", Physiol. Res. 46(3), 233-235. 3. Kotala, V., et al., (2001), "Potent induction of wild-type p53-dependent transcription in tumour cells by a synthetic inhibitor of cyclin-dependent kinases", Cell Mol. Life Sci., 58(9): 1333-1339. 4. Kolar, Z., et al., (2000), "Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer", Mol. Pathol., 53(1): 15-18.